Biotinylated Human Fc gamma RIIIA / CD16a (F176) Protein, Avitag™,His Tag (SPR & BLI & MALS verified)
分子别名（Synonym）
FCGR3A, CD16A, FCG3, FCGR3, IGFR3
表达区间及表达系统（Source）
Biotinylated Human CD16a (F176), Avitag,His Tag (CDA-H82E8) is expressed from human 293 cells (HEK293). It contains AA Gly 17 - Gln 208 (Accession # P08637-1).
Predicted N-terminus: Gly 17
蛋白结构（Molecular Characterization）
This protein carries an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag.
The protein has a calculated MW of 25.5 kDa. The protein migrates as 40-55 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
标记（Labeling）
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白标记度（Protein Ratio）
Passed as determined by the HABA assay / binding ELISA.
纯度（Purity）
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 12 months under sterile conditions after reconstitution.
背景介绍
CD16作为低亲和力Fc受体，包含FcγRIIIa（CD16a）与FcγRIIIb（CD16b）两种亚型，二者均特异性结合IgG抗体的Fc段并由高度同源基因以细胞类型特异性方式编码，表达于自然杀伤细胞、中性粒细胞、单核细胞及巨噬细胞表面。其中CD16a（低亲和力免疫球蛋白γ Fc段受体III-A）作为中亲和力跨膜糖蛋白（多肽锚定），分布于NK细胞、巨噬细胞、T细胞亚群、未成熟胸腺细胞及胎盘滋养层细胞，介导吞噬作用、酶类与炎症介质分泌、抗体依赖性细胞毒性及免疫复合物清除；而CD16b则是中性粒细胞和嗜酸性粒细胞表达的低亲和力GPI锚定受体。CD16a的功能异常与复发性病毒感染易感性、系统性红斑狼疮及同种免疫性新生儿中性粒细胞减少症密切相关。
关键字： Fc gamma RIIIA;FCGR3A蛋白;CD16A重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。